A phase Ib/II trial of lenvatinib (len) and letrozole (let) incorporating pharmacodynamics studies in postmenopausal women with hormone receptor positive (HR plus ) locally advanced/metastatic breast cancer (LABC/MBC).

被引：2
|
作者：
Lim, Joline Si Jing
Wong, Andrea Li Ann
Ow, Samuel Guan Wei
Eng, Lim Siew
Sundar, Raghav
Chan, Gloria H. J.
Yadav, Kritika
Heong, Valerie
Tan, David Shao Peng
Soo, Ross A.
Chee, Cheng Ean
Yong, Wei-Peng
Goh, Boon C.
Lee, Soo-Chin
机构：
[1] Natl Univ Canc Inst, Singapore, Singapore
[2] Canc Sci Inst, Singapore, Singapore
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.1045
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1045
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Clinical efficacy and molecular effects of lenvatinib (Len) and letrozole (Let) in hormone receptor-positive (HR plus ) metastatic breast cancer (MBC).
    Lim, Joline Si Jing
    Wong, Andrea
    Ow, Samuel Guan Wei
    Ngoi, Natalie
    Ang, Yvonne Li'en
    Chan, Gloria
    Eng, Lim Siew
    Chong, Wan Qin
    Choo, Joan
    Lee, Matilda
    Tan, Hon Lyn
    Jan, Yi-hua
    Tan, Kien Thiam
    Sundar, Raghav
    Tan, David Shao Peng
    Soo, Ross A.
    Chee, Cheng Ean
    Yong, Wei-Peng
    Goh, Boon C.
    Lee, Soo-Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer
    Lim, Joline S. J.
    Wong, Andrea L. A.
    Ow, Samuel G. W.
    Ngoi, Natalie Y. L.
    Chan, Gloria H. J.
    Ang, Yvonne L. E.
    Chong, Wan Qin
    Lim, Siew Eng
    Lim, Yi Wan
    Lee, Matilda
    Choo, Joan R. E.
    Tan, Hon Lyn
    Yong, Wei Peng
    Soo, Ross A.
    Tan, David S. P.
    Chee, Cheng Ean
    Sundar, Raghav
    Yadav, Kritika
    Jain, Supriya
    Wang, Lingzhi
    Tai, Bee Choo
    Goh, Boon Cher
    Lee, Soo-Chin
    CLINICAL CANCER RESEARCH, 2022, 28 (11) : 2248 - 2256
  • [3] Phase I/II study of letrozole and sorafenib as first-line therapy of hormone-receptor positive (HR plus ) metastatic breast cancer (MBC).
    Tan, Antoinette R.
    Wong, Serena Tsan-Lai
    Warren, Robert D.
    Eng-Wong, Jennifer
    Liu, Minetta C.
    Zelnak, Amelia Bruce
    Lin, Yong
    Shih, Weichung
    Ganesan, Shridar
    Grana, Generosa
    Isaacs, Claudine
    Toppmeyer, Deborah
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] A phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefinitib with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Cristofanilli, M.
    Valero, V.
    Mangalik, A.
    Rabinowitz, I.
    Arena, F. P.
    Kroener, J. F.
    Curcio, E.
    Watkins, C.
    Magill, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR plus ) metastatic breast cancer (MBC): first results from the EGF30008 Trial
    Johnston, S.
    Pegram, M.
    Press, M.
    Pippen, J.
    Pivot, X.
    Gomez, H.
    Florance, A.
    O'Rourke, L.
    Maltzman, J.
    CANCER RESEARCH, 2009, 69 (02) : 74S - 75S
  • [6] Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer
    Ibrahim, Nuhad K.
    Yariz, Kemal O.
    Bondarenko, Ihor
    Manikhas, Alexei
    Semiglazov, Vladimir
    Alyasova, Anna
    Komisarenko, Volodymyr
    Shparyk, Yaroslav
    Murray, James Lee
    Jones, David
    Senderovich, Shai
    Chau, Albert
    Erlandsson, Fredrik
    Acton, Gary
    Pegram, Mark
    CLINICAL CANCER RESEARCH, 2011, 17 (21) : 6822 - 6830
  • [7] Patterns of care and patient characteristics in postmenopausal women with HER2+and hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Sharma, P. P.
    Sail, K.
    Delea, T. E.
    Forsyth, M. T.
    Halm, M.
    Nagarwala, Y. M.
    Lopez, W.
    Patt, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Src Kinase Inhibition with AZD0530 Plus Anastrozole in Postmenopausal Hormone Receptor Positive (HR plus ) Metastatic Breast Cancer (MBC)
    Pegram, M.
    Silva, O.
    Higgins, C.
    Tukia, K.
    Avisar, E.
    Stuart, M.
    Slingerland, J.
    CANCER RESEARCH, 2010, 70
  • [9] Palbociclib in combination with fulvestrant or tamoxifen as treatment for hormone receptor positive (HR plus ) metastatic breast cancer (MBC) with prior chemotherapy for advanced disease (TBCRC 035) A phase II study with pharmacodynamics markers
    Rugo, H. S.
    Mayer, E. L.
    Storniolo, A. M.
    Isaacs, C.
    Mayer, I.
    Stearns, V.
    Nanda, R.
    Nangia, J.
    Wabl, C.
    Deluca, A.
    Kochupurakkal, B.
    Wolff, A. C.
    Shapiro, G. I.
    CANCER RESEARCH, 2019, 79 (04)
  • [10] A phase II study of pembrolizumab in combination with palliative radiotherapy (RT) for hormone receptor-positive (HR plus ) metastatic breast cancer (MBC).
    Barroso-Sousa, Romualdo
    Krop, Ian E.
    Trippa, Lorenzo
    Tan-Wasielewski, Zhenying
    Li, Tianyu
    Osmani, Wafa
    Andrews, Chelsea
    Dillon, Deborah
    Richardson, Edward T.
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Schoenfeld, Jonathan Daniel
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345